The Record... (cont'd)
Sharon,
I know you didn't ask for this, but I thought you might want some additional marketing data on vatalanib .
I am sending you the rating information from Pharmaprojects in case it is of use to you. It's early, but it appears that this drug has a high potential for sales.
Ric
One last field on marketing in Pharmaprojects that Sharon might want to see is the Ratings system. This field includes:
Novelty ratings
Market size
Development speed
A Total rating
This combination of ratings provides users of the file with an opportunity to see which drugs in research and development are potentially the most interesting and important.
The Update field allows for further refinements, especially if we are doing a current awareness search, where we want to keep up to date on a regular basis with the status of this drug. This field provides the latest status worldwide, as well as a history of the drug's status in all countries.
RATING: Novelty: 6 (Leading Compound) 
Development Speed: 4 (Faster than Average)
Market Size: 3 (US$ 2001-5000 million)
Total Rating: 13 (Total Rating)
MAJOR EVENTS
Event Date A/E Event--Details
20060119 Est New Indication--Macular degeneration
20050124 Est New Therapeutic Activity--Ophthalmological
20031119 Est Pharmacology Identified--VEGFR-1 and -3
kinase inhibitors KI-GFEN1- and KI-GFEN3-
20030123 Est Change in Status--Phase III Clinical Trial
20021121 Est New Indication--Cancer, renal and cancer, brain
20010621 Est New Indication--Cancer, colorectal
20010601 Act Names Granted--ZK-222584
20010515 Est Change in Status--Phase I/II Clinical Trial
20000803 Act New Chemical Structure--New
20000705 Act New Product in Pharmaprojects
The Latest update appears higher in the record, following New Entity.
Latest Upd: Updated On By Latest Change
20070119 JB Filing plans updated
This part of the record gives a history of the development of valatanib.
Go to the next page.
